Rua Bioscience Ltd. 2022 AR2
The report highlights Rua Bioscience's progress during the 2022 fiscal year, including obtaining Good Manufacturing Practice (GMP) certification from Medsafe and launching its first medicine in New Zealand. The company expanded its global reach by acquiring Zalm Therapeutics, securing a long-term supply contract with Cann Group, and obtaining a narcotic license for the German market. Financially, Rua reported a loss before tax of $7.49 million, which was in line with expectations as a pre-revenue start-up. On sustainability, the company initiated its carbon footprint measurement with Toitū Envirocare and established a community impact measurement framework.
Company: Rua Bioscience Ltd.
Sector: Manufacturing
Country: New Zealand
Year: 2022
Type: AR2
Pages: 104
Back to company
Rua Bioscience Ltd.
Annual Report
The report highlights Rua Bioscience's progress during the 2022 fiscal year, including obtaining Good Manufacturing Practice (GMP) certification from Medsafe and launching its first medicine in New Zealand. The company expanded its global reach by acquiring Zalm Therapeutics, securing a long-term supply contract with Cann Group, and obtaining a narcotic license for the German market. Financially, Rua reported a loss before tax of $7.49 million, which was in line with expectations as a pre-revenue start-up. On sustainability, the company initiated its carbon footprint measurement with Toitū Envirocare and established a community impact measurement framework.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jul 1, 2021 - Jun 30, 2022
Fiscal Year
2022
Published
Sep 14, 2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees